AACR 2023 -- Clinically lung cancer often metastasizes to the brain, significantly reducing life expectancy. Many patients with non-small cell lung cancer (NSCLC) already have brain metastasis when they are first diagnosed.
AACR 2023 -- Tumor microenvironment (TME) is rich in cells that potentially inhibit T cell function, such as regulatory T cells (Tregs) and myeloid derived suppressor cells (MDSCs).
AACR 2023 -- The prognosis for people with pancreatic cancer is poor, with an average 5-year survival rate of 10% and only 3% for those with metastatic illness. Pancreatic cancer patients have few therapeutic options, and innovative therapies are sorely needed to improve treatment of the disease.
AACR 2023 -- Triple immunodeficient mouse models are often necessary to evaluate xenograft models and adoptive cell therapies using human immune cells. Triple immunodeficient mice lack functional T cells, B cells and natural killer (NK) cells.
CASSS US Bioassay 2023 -- The transfer of cell-based potency methods is a necessary requirement to support the CMC drug development lifecycle. Method transfer may be between labs within the same company or externally to one or even multiple external sites (e.g., CDMOs, CROs).
SETAC Europe 2023 -- Environmental risk assessments (ERAs) for chemical, crop protection products and pharmaceuticals are necessary to fulfil global registration requirements. The data needed to describe environmental fate and aquatic or terrestrial hazards can lead to large testing programs and potentially high vertebrate usage.
AIT 2023 -- In pharmaceutical, agrochemical and industrial chemical testing, specific systems are desirable in order to effectively handle all quantities of test articles in a complete range of physical states.
AIT 2023 -- Initial technical trials delivering an oligonucleotide test material formulated into ultrapure water using a partner-designated clinical mesh micropump delivery platform identified two nebulizer performance challenges that were each capable of limiting the required nonclinical program.
CASSS AT Europe 2023 -- LC-MS peptide multi-attribute monitoring (MAM) provides primary sequence critical quality attribute (CQA) data in a single assay. MAM has been applied to re-evaluate the Pembrolizumab formulation. Pembrolizumab is an IgG4 immunotherapy that binds to the PD‑1 receptor of T-cells to induce an immune response against tumor cells.
